Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patientsI Jolanda M de Vries, W Joost Lesterhuis, Nicole M Scharenborg, et al.Cancer Immunology Research|June 22, 2014
Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugatesGijs G Zom, Selina Khan, Cedrik M Britten, et al.Cancer Immunology, Immunotherapy : CII|August 20, 2014
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer stainingLindsey Chudley, Katy J McCann, Adam Coleman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2006
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanomaMikhail Pashenkov, Gerda Goëss, Christine Wagner, et al.Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.Cancer Immunology, Immunotherapy : CII|July 1, 2015
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometrySaskia J A M Santegoets, Eveline M Dijkgraaf, Alessandra Battaglia, et al.Standards in Genomic Sciences|February 10, 2011
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshopCarsten Kettner, Dawn Field, Susanna-Assunta Sansone, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2021
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βJonathan D Silk, Rachel J M Abbott, Katherine J Adams, et al.Journal for Immunotherapy of Cancer|July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersLisa H Butterfield, A Karolina Palucka, Cedrik M Britten, et al.Pageof 6